<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637256</url>
  </required_header>
  <id_info>
    <org_study_id>037.HPB.2018.R</org_study_id>
    <nct_id>NCT04637256</nct_id>
  </id_info>
  <brief_title>Evaluation of Outcomes From Treatment of Benign or Malignant Gastroesophageal Diseases</brief_title>
  <official_title>Evaluation of Outcomes From Treatment of Benign or Malignant Gastroesophageal Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a retrospective chart review of patients who have been diagnosed with&#xD;
      benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr.&#xD;
      Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in&#xD;
      Richardson, TX. The Investigators plan to conduct an analysis of patients meeting the&#xD;
      inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is,&#xD;
      surgery fellows, office staff and clinical research coordinator who are delegated to do by&#xD;
      the PI. Data will be obtained by looking through either the investigator's patients from&#xD;
      their practice or through a national database. Data will be analyzed primarily by the study&#xD;
      conductors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. INTRODUCTION 1.1. Background It is reported in the literature that the treatment of any&#xD;
      gastroesophageal disease process, whether benign or malignant, continues to be a huge&#xD;
      challenge. For example, patients with esophageal cancer continue to be diagnosed at an&#xD;
      advanced stage with medical and surgical options that are improving in terms of outcome&#xD;
      measurements but with much more room for improvement. The Primary investigtor goal is to&#xD;
      continue to review patient treatment outcomes to further improve overall survival, overall&#xD;
      symptom control, mortality and morbidity.&#xD;
&#xD;
      1.2. Aim(s)/Objective(s) The main aim of this study is to evaluate and compare the outcomes&#xD;
      from the investigator's treatment of benign or gastroesophageal diseases.&#xD;
&#xD;
      1.3. Rationale for the study There is a need to understand and improve the current diagnosis&#xD;
      and treatment algorithm for gastroesophageal pathologies. Continued evaluation and study is&#xD;
      imperative to ensure that national guidelines are improving to enhance patient cure and/or&#xD;
      recovery.&#xD;
&#xD;
      2. OBJECTIVES AND STUDY OUTCOME MEASURES 2.1. Study Objectives 2.1.1. Primary Objective(s)&#xD;
&#xD;
      • To evaluate and compare the outcomes from the investigator's treatment of benign or&#xD;
      malignant gastroesophageal disease 2.2. Study Outcome Measures 2.2.1. Primary Outcome(s)&#xD;
&#xD;
        -  To exam all treatments of benign or malignant gastroesophageal disease by measuring the&#xD;
           following outcomes o Overall survival o Overall symptom control&#xD;
&#xD;
           o Mortality&#xD;
&#xD;
           o Morbidity 4. STUDY ENROLLMENT AND WITHDRAWAL 4.1. Study Inclusion Criteria:&#xD;
&#xD;
        -  All patients diagnosed and treated for gastroesophageal diseases, benign or malignant&#xD;
           from 2005 to present.&#xD;
&#xD;
        -  Age ≥18 years 4.2. Study Exclusion Criteria:&#xD;
&#xD;
        -  Patients that are not diagnosed with or treated for gastroesophageal diseases&#xD;
&#xD;
        -  Age &lt; 18 years 5. STATISTICAL CONSIDERATIONS 5.1. Sample Size Considerations All past&#xD;
           patients who were treated for a particular benign or malignant gastroesophageal disease&#xD;
           process under evaluation from 2005 to present will be included in this study.&#xD;
&#xD;
      5.2. Statistical Analysis Plan Statistics will be provided for all data obtained. Normally&#xD;
      distributed continuous outcomes will be analyzed with Student's t test and non-normally&#xD;
      distributed continuous outcomes will be analyzed with nonparametric Wilcoxon-Mann-Whitney&#xD;
      test. Categorical outcomes will be analyzed using chi-square test or Fisher's exact test for&#xD;
      smaller samples.&#xD;
&#xD;
      6. ETHICS/PROTECTION OF HUMAN SUBJECTS 6.1. Ethical Standard 6.1.1. The following safeguard&#xD;
      will be employed to protect confidentiality of data&#xD;
&#xD;
        -  Limitation of access to data&#xD;
&#xD;
        -  Minimal HIPAA identifiers on data collection tools&#xD;
&#xD;
        -  Password protected share drive database on computer&#xD;
&#xD;
        -  Use of locked file cabinets for physical records (if any collected)&#xD;
&#xD;
        -  Restricted access to share drive database on computers&#xD;
&#xD;
        -  Appropriate training of personnel accessing share drive database&#xD;
&#xD;
        -  At close of this study, all identifiers will be removed from the data collection tools&#xD;
           6.2. Institutional Review Board The protocol and all study related materials will be&#xD;
           submitted to the IRB for review and approval. Approval of both the protocol and study&#xD;
           related material will be obtained before any clinical data is collected. Any amendment&#xD;
           to the protocol will require review and approval by the IRB before the changes are&#xD;
           implemented in the study.&#xD;
&#xD;
      6.3. Informed Consent Process 6.3.1. Details to waive consent for this retrospective chart&#xD;
      review&#xD;
&#xD;
      • This research is not regulated by the FDA&#xD;
&#xD;
        -  The research involves no more than minimal risk to the subjects&#xD;
&#xD;
        -  The waiver or alternation will not adversely affect the rights or welfare of the&#xD;
           subjects&#xD;
&#xD;
        -  The research could not practicably be carried out without the waiver&#xD;
&#xD;
        -  It is not feasible to provide subjects with pertinent information after participation&#xD;
           6.4. Participant Confidentiality&#xD;
&#xD;
        -  All data collection will be kept in password protected hospital server&#xD;
&#xD;
        -  Only authorized personal will have access share drive&#xD;
&#xD;
        -  Patient confidentiality will be maintained at all times, complying with HIPAA&#xD;
           guidelines.&#xD;
&#xD;
           7. DATA MANAGEMENT PLAN 7.1. Source Document Management&#xD;
&#xD;
      The investigator(s)/institution(s) will permit study-related monitoring, audits, IEC/IRB&#xD;
      review, and regulatory inspection(s), providing direct access to data collected via the&#xD;
      Methodist Health System share drive. Data collected during this study will be recorded on the&#xD;
      appropriate data source via word document, access database, and excel spread sheet depending&#xD;
      on treatment type capturing the following data but not limited to:&#xD;
&#xD;
        -  • Demographics&#xD;
&#xD;
             -  Subject number&#xD;
&#xD;
             -  First and Last Name&#xD;
&#xD;
             -  Medical Record Number&#xD;
&#xD;
             -  Social Security&#xD;
&#xD;
             -  Gender&#xD;
&#xD;
             -  Ethnicity&#xD;
&#xD;
             -  Race&#xD;
&#xD;
             -  Date of Birth&#xD;
&#xD;
        -  Diagnosis&#xD;
&#xD;
             -  Date of Diagnosis&#xD;
&#xD;
             -  Age at Diagnosis&#xD;
&#xD;
             -  Class of Case&#xD;
&#xD;
             -  Symptoms Associated with Diagnosis Onset date Length of Symptom On set&#xD;
&#xD;
             -  Eckcardt Score&#xD;
&#xD;
             -  Clinical T&#xD;
&#xD;
             -  Clinical N&#xD;
&#xD;
             -  Clinical M&#xD;
&#xD;
             -  Clinical Stage&#xD;
&#xD;
             -  R Status&#xD;
&#xD;
             -  Pre-Op Work Up and Results&#xD;
&#xD;
             -  Date of 1st Contact&#xD;
&#xD;
             -  Zip code at Diagnosis&#xD;
&#xD;
        -  Medical History&#xD;
&#xD;
             -  Diagnosis&#xD;
&#xD;
             -  On set Date&#xD;
&#xD;
        -  Medication List&#xD;
&#xD;
             -  Name&#xD;
&#xD;
             -  Dose&#xD;
&#xD;
             -  Frequency&#xD;
&#xD;
        -  Social Medical History&#xD;
&#xD;
             -  Depression&#xD;
&#xD;
             -  Tobacco Never Smoked Current Smoker&#xD;
&#xD;
        -  Amount of Cigarettes per day/week Ex-Smoker&#xD;
&#xD;
        -  Date of Quitting&#xD;
&#xD;
        -  Amount of Cigarettes per day/week&#xD;
&#xD;
           o Alcohol Never Consumed Alcohol&#xD;
&#xD;
        -  Amount of consumption per day/week/month Current Alcohol User&#xD;
&#xD;
        -  Amount of consumption per day/week/month&#xD;
&#xD;
             -  Jaundice&#xD;
&#xD;
             -  Drug/ Substance Abuse&#xD;
&#xD;
             -  Reported Weight Loss Weight lbs. and kg. Length of Weight Loss on set&#xD;
&#xD;
        -  Anesthesia&#xD;
&#xD;
             -  Type of Anesthesia&#xD;
&#xD;
             -  ASA&#xD;
&#xD;
             -  Anesthesia Start and End Time&#xD;
&#xD;
             -  Medication list Name Dose Frequency&#xD;
&#xD;
             -  Intra-Ops I/O's&#xD;
&#xD;
             -  Est. Blood loss (ml)&#xD;
&#xD;
             -  Blood Transfusions&#xD;
&#xD;
             -  Patient Position&#xD;
&#xD;
             -  Complication&#xD;
&#xD;
             -  Notes&#xD;
&#xD;
        -  Surgery&#xD;
&#xD;
             -  Date&#xD;
&#xD;
             -  Age at Surgery Visit&#xD;
&#xD;
             -  Pre-op Stent&#xD;
&#xD;
             -  TPN&#xD;
&#xD;
             -  Primary Site&#xD;
&#xD;
             -  Classification of Diagnosis&#xD;
&#xD;
             -  Pre-Op Diagnosis&#xD;
&#xD;
             -  Post-Op Diagnosis&#xD;
&#xD;
             -  Proposed Procedure&#xD;
&#xD;
             -  Actual Procedure&#xD;
&#xD;
             -  Laparoscopic&#xD;
&#xD;
             -  Laparotomy&#xD;
&#xD;
             -  Pylorus preserved&#xD;
&#xD;
             -  Procedure Start and end time&#xD;
&#xD;
             -  Operative time&#xD;
&#xD;
             -  Prophylactic antibiotic&#xD;
&#xD;
             -  Intra-op antibiotic redoes&#xD;
&#xD;
             -  Ng tube&#xD;
&#xD;
             -  Adjusted Est. Blood Loss&#xD;
&#xD;
             -  Est. Blood loss (ml)&#xD;
&#xD;
             -  Drains inserted&#xD;
&#xD;
             -  Specimens Collected&#xD;
&#xD;
             -  Specimen Results&#xD;
&#xD;
             -  Complications&#xD;
&#xD;
             -  Hospital and Discharge Medication List&#xD;
&#xD;
             -  Name&#xD;
&#xD;
             -  Dose&#xD;
&#xD;
             -  Frequency&#xD;
&#xD;
             -  Post Medication List&#xD;
&#xD;
             -  Name&#xD;
&#xD;
             -  Dose&#xD;
&#xD;
             -  Frequency&#xD;
&#xD;
        -  Vitals&#xD;
&#xD;
           o In the following times points: Pre-Op, Intra-Op, Post-Op, and Discharge Systolic&#xD;
           Diastolic Pulse rate Temperature Respiration BMI&#xD;
&#xD;
        -  Lab&#xD;
&#xD;
             -  In the following time points: Pre-op and Post-op at different F/U Visit AST ALT ALP&#xD;
                TOTAL BILIRUBIN DIRECT BILIRUBIN TOTAL PROTEIN PRE ALBUMIN ALBUMIN CA 19-9 CEA CRP&#xD;
                WBC/ LEUKOCYTES HGB HCT MCV PLATELETS BIOCARBONATE (TOTAL CO2) AFP AMYLASE LIPASE&#xD;
                JP AMYLASE&#xD;
&#xD;
        -  Pathology&#xD;
&#xD;
             -  Final Diagnosis&#xD;
&#xD;
             -  Diagnosis Comment&#xD;
&#xD;
             -  Clinical Information&#xD;
&#xD;
             -  Gross Description&#xD;
&#xD;
             -  Microscopic Description&#xD;
&#xD;
             -  Diagnosis histology&#xD;
&#xD;
             -  Benign/malignant&#xD;
&#xD;
             -  Pathology T&#xD;
&#xD;
             -  Pathology N&#xD;
&#xD;
             -  Pathology M&#xD;
&#xD;
             -  Pathology Stage&#xD;
&#xD;
             -  R status&#xD;
&#xD;
             -  Grade&#xD;
&#xD;
             -  Tumor size (cm)&#xD;
&#xD;
             -  All Margins&#xD;
&#xD;
             -  All Lymph Nodes&#xD;
&#xD;
             -  Perineural invasion&#xD;
&#xD;
             -  Lymph invasion&#xD;
&#xD;
             -  Vascular invasion&#xD;
&#xD;
             -  SPN LN&#xD;
&#xD;
             -  LBD LN&#xD;
&#xD;
             -  Regional LN examined&#xD;
&#xD;
             -  Regional LN positive&#xD;
&#xD;
        -  Imaging&#xD;
&#xD;
             -  Pre-op CT Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
             -  Pre-op MRI Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
             -  Pre-op PET Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
             -  Post-op CT at Different F/U Visit Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
             -  Post-op MRI at Different F/U Visit Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
             -  Post-op PET at Different F/U Visit Date of Exam Type of Exam Findings/Impressions&#xD;
&#xD;
        -  Inpatient&#xD;
&#xD;
             -  Admission date&#xD;
&#xD;
             -  Discharge date&#xD;
&#xD;
             -  LOS (days)&#xD;
&#xD;
             -  LOS after surgery (days)&#xD;
&#xD;
             -  Direct floor transfer&#xD;
&#xD;
             -  ICU stay&#xD;
&#xD;
             -  ICU admission date&#xD;
&#xD;
             -  ICU discharge date&#xD;
&#xD;
             -  Length of ICU stay (days)&#xD;
&#xD;
             -  Tube feed&#xD;
&#xD;
             -  TF #&#xD;
&#xD;
             -  TF start date&#xD;
&#xD;
             -  TF end date&#xD;
&#xD;
             -  TF Post-OP&#xD;
&#xD;
             -  Oral&#xD;
&#xD;
             -  Oral start date&#xD;
&#xD;
             -  Oral post-op&#xD;
&#xD;
             -  Reglan&#xD;
&#xD;
             -  Entereg&#xD;
&#xD;
             -  Entereg 1st oral intake&#xD;
&#xD;
             -  Bowel movement date&#xD;
&#xD;
             -  Time to 1st of bowel movement (days)&#xD;
&#xD;
             -  Medication list Name Dose Frequency&#xD;
&#xD;
             -  Complications&#xD;
&#xD;
             -  Discharge Diagnosis&#xD;
&#xD;
        -  Complications&#xD;
&#xD;
             -  Readmit within 30 days of d/c&#xD;
&#xD;
             -  Reason for readmit&#xD;
&#xD;
             -  Delayed gastric emptying&#xD;
&#xD;
             -  Pancreatic fistula&#xD;
&#xD;
             -  Wound infection&#xD;
&#xD;
             -  Intraabdominal abscess&#xD;
&#xD;
             -  Cardiac event&#xD;
&#xD;
             -  Pancreatitis&#xD;
&#xD;
             -  Bile leak&#xD;
&#xD;
             -  Pneumonia&#xD;
&#xD;
             -  Hemobilia&#xD;
&#xD;
             -  Lymphatic leak&#xD;
&#xD;
             -  Pancreatic leak&#xD;
&#xD;
             -  GI bleed&#xD;
&#xD;
             -  Anemia&#xD;
&#xD;
             -  Reoperation&#xD;
&#xD;
             -  Other morbidities&#xD;
&#xD;
        -  Comorbidities&#xD;
&#xD;
             -  Cerebrovascular Accident&#xD;
&#xD;
             -  Peripheral Vascular Disease&#xD;
&#xD;
             -  Diabetes&#xD;
&#xD;
             -  Hypertension&#xD;
&#xD;
             -  MYO Card Infarct&#xD;
&#xD;
             -  COPD&#xD;
&#xD;
             -  Malnutrition&#xD;
&#xD;
             -  CHF&#xD;
&#xD;
             -  Revised co-morb scale&#xD;
&#xD;
             -  Other&#xD;
&#xD;
        -  Pre-Op and Post-op Chemo and Radiation o Chemo start date&#xD;
&#xD;
           o Chemo end date&#xD;
&#xD;
             -  Chemo regimen&#xD;
&#xD;
             -  # of completed cycles&#xD;
&#xD;
             -  Pre-op or post-op or both&#xD;
&#xD;
             -  Patient declined&#xD;
&#xD;
             -  Contraindicated&#xD;
&#xD;
             -  Course date radiation started&#xD;
&#xD;
             -  Course date radiation ended&#xD;
&#xD;
             -  Dose&#xD;
&#xD;
             -  Fractions&#xD;
&#xD;
        -  Post Op Follow up Clinical/Phone Visit&#xD;
&#xD;
           o Follow Up Visit Date&#xD;
&#xD;
             -  Symptoms Reported&#xD;
&#xD;
             -  Length of Symptom On set&#xD;
&#xD;
             -  Medication list Name Dose Frequency&#xD;
&#xD;
             -  Eckcardt Score&#xD;
&#xD;
        -  Patient Outcome o Site of recurrence&#xD;
&#xD;
           o Date of recurrence&#xD;
&#xD;
           o Clinical/path dx recurrence&#xD;
&#xD;
           o Recurrence&#xD;
&#xD;
             -  Recurrence Surgery Date&#xD;
&#xD;
             -  Disease free&#xD;
&#xD;
             -  Follow up&#xD;
&#xD;
             -  Date of death&#xD;
&#xD;
             -  Post op mortality&#xD;
&#xD;
      7.2. Data Capture Methods • Data will be collected and entered at MRMC&#xD;
&#xD;
      • Data will be captured from Methodist Health System eMAR and TSC Clinical eMAR&#xD;
&#xD;
      • A secure Methodist Health System share drive will host all data&#xD;
&#xD;
      • Training and access to share drive will be given to all study staff as delegated per PI&#xD;
&#xD;
      • Data collected during this study will be recorded on the appropriate data source via word&#xD;
      document, access database, and/or excel spread sheet depending on treatment type capturing&#xD;
      the following data but not limited to demographics, treatment, pre-operative evaluation,&#xD;
      surgical technique, hospitalization, and post-operative evaluation. Stored insecure share&#xD;
      drive with access limited to study staff in a password protected computer at MRMC&#xD;
&#xD;
      8. PUBLICATION PLAN All information will be blinded in compliance with GCP. The investigator&#xD;
      will make all possible efforts to ensure compliance with all policies regarding sharing of&#xD;
      PHI or research information. Only de-identified PHI will be shared in relevant research&#xD;
      mediums. These mediums may range from national, regional, local and/or international sites.&#xD;
      In addition, study data and findings may be submitted for presentation at local and national&#xD;
      conferences&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2005 to 2019</time_frame>
    <description>We will be examining all treatments of benign or malignant pancreatic cancer by measuring the following outcome: overall survival</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pancreatic Malignant Neoplasm Primary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All past patients who were treated for a particular benign or malignant gastroesophageal&#xD;
        disease process under evaluation from 2005 to present will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients diagnosed and treated for gastroesophageal diseases, benign or malignant&#xD;
             from 2005 to present.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that are not diagnosed with or treated for gastroesophageal diseases&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhiresh Jeyarajah, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystee Cooper, DHEd</last_name>
    <phone>214-947-1280</phone>
    <email>CrysteeCooper@mhd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitasha Phatak, Ph.D.</last_name>
    <phone>214-947-4459</phone>
    <email>NitashaPhatak@mhd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trinity Surgical Consultants, Methodist Richardson Medical Center</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhiresh R Jeyarajah, MD</last_name>
      <phone>972-619-3500</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

